[go: up one dir, main page]

WO2006033912A3 - Treatment of bone disorders with skeletal anabolic drugs - Google Patents

Treatment of bone disorders with skeletal anabolic drugs Download PDF

Info

Publication number
WO2006033912A3
WO2006033912A3 PCT/US2005/032706 US2005032706W WO2006033912A3 WO 2006033912 A3 WO2006033912 A3 WO 2006033912A3 US 2005032706 W US2005032706 W US 2005032706W WO 2006033912 A3 WO2006033912 A3 WO 2006033912A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bone disorders
anabolic drugs
skeletal anabolic
skeletal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032706
Other languages
French (fr)
Other versions
WO2006033912B1 (en
WO2006033912A2 (en
Inventor
Andrew F Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osteotrophin LLC
Original Assignee
Osteotrophin LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteotrophin LLC filed Critical Osteotrophin LLC
Priority to AU2005287139A priority Critical patent/AU2005287139A1/en
Priority to EP05797693A priority patent/EP1799240A4/en
Priority to MX2007003185A priority patent/MX2007003185A/en
Priority to CA002580281A priority patent/CA2580281A1/en
Priority to JP2007532415A priority patent/JP2008513459A/en
Publication of WO2006033912A2 publication Critical patent/WO2006033912A2/en
Publication of WO2006033912A3 publication Critical patent/WO2006033912A3/en
Publication of WO2006033912B1 publication Critical patent/WO2006033912B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.
PCT/US2005/032706 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs Ceased WO2006033912A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005287139A AU2005287139A1 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs
EP05797693A EP1799240A4 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs
MX2007003185A MX2007003185A (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs.
CA002580281A CA2580281A1 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs
JP2007532415A JP2008513459A (en) 2004-09-16 2005-09-14 Method for treating bone diseases using bone anabolic substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61028304P 2004-09-16 2004-09-16
US60/610,283 2004-09-16

Publications (3)

Publication Number Publication Date
WO2006033912A2 WO2006033912A2 (en) 2006-03-30
WO2006033912A3 true WO2006033912A3 (en) 2006-06-29
WO2006033912B1 WO2006033912B1 (en) 2006-09-08

Family

ID=36090476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032706 Ceased WO2006033912A2 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs

Country Status (6)

Country Link
EP (1) EP1799240A4 (en)
JP (1) JP2008513459A (en)
AU (1) AU2005287139A1 (en)
CA (1) CA2580281A1 (en)
MX (1) MX2007003185A (en)
WO (1) WO2006033912A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346714B (en) * 2007-08-01 2017-03-24 The General Hospital Corp * Screening methods using g-protein coupled receptors and related compositions.
BR112012013725A2 (en) 2009-12-07 2017-01-10 Univ Michigan Tech black bear parathyroid hormone and methods of using the black bear parathyroid hormone.
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171288A1 (en) * 2002-01-10 2003-09-11 Stewart Andrew F. Treatment of bone disorders with skeletal anabolic drugs
WO2003099849A2 (en) * 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171288A1 (en) * 2002-01-10 2003-09-11 Stewart Andrew F. Treatment of bone disorders with skeletal anabolic drugs
WO2003099849A2 (en) * 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1799240A4 *

Also Published As

Publication number Publication date
JP2008513459A (en) 2008-05-01
EP1799240A4 (en) 2009-07-22
CA2580281A1 (en) 2006-03-30
AU2005287139A1 (en) 2006-03-30
MX2007003185A (en) 2007-10-16
EP1799240A2 (en) 2007-06-27
WO2006033912B1 (en) 2006-09-08
WO2006033912A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2003059291A3 (en) Treatment of bone disorders with skeletal anabolic drugs
WO2005046603A3 (en) Pyridine compounds
TW200612892A (en) Novel compounds
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2008063867A3 (en) Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2008137787A3 (en) Combination therapy with a compound acting as a platelet adp receptor inhibitor
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
WO2007092065A3 (en) Compounds and compositions as lxr modulators
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2005105110A3 (en) Doxepin analogs and methods of use thereof
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (en) Method for preventing and treating diabetes using neurturin
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2006066011A3 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
WO2006036813A3 (en) 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580281

Country of ref document: CA

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003185

Country of ref document: MX

Ref document number: 2007532415

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005287139

Country of ref document: AU

Date of ref document: 20050914

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1236/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005797693

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005797693

Country of ref document: EP